Spine biopharma sb 01 The dominant search intent for "sb01 peptide" is to understand what this synthetic peptide is, its composition, its mechanism of action, and its clinical development, particularly concerning its potential to treat chronic low back pain caused by degenerative disc disease.Spine Biopharma Study
Core Entities & High-Relevance Phrases (Tier 1):
* sb01 peptide
* synthetic 7-amino acid peptide
* Vicatertide (also known as SB-01)
* Transforming Growth Factor Beta 1 (TGF-β1)
* antagonizes TGF-β activity/inhibitor
* chronic low back pain
* degenerative disc disease (DDD)
* SB-01 For Injection
Supporting Entities & Concepts (Tier 2):
* Spine BioPharma
* down-regulation of TGF-β1
* pleiotropic cytokine
* intradiscal pharmacologic treatment
* pain-related function
* orthopaedic sports medicine
* peripheral nerve injury
* Remedisc
Weaker/Repetitive/Potentially Noisy Terms (Tier 3):
* SBP1 peptide (different peptide)
* SB01 - StabilBlot™ Protein-Free Blocker (unrelated product)
* YH14618 (appears to be a research code for SB-01)
* "SB-01 peptide for sale," "Sb 01 peptide reddit" (commercial/forum-based, not core scientific info)
---
The sb01 peptide, known scientifically as Vicatertide, is a synthetic 7-amino acid peptide developed to target inflammation associated with certain medical conditions. Its primary focus in clinical development has been as a potential treatment for chronic low back pain stemming from degenerative disc disease (DDD). By acting as an inhibitor, SB-01 aims to modulate the activity of Transforming Growth Factor Beta 1 (TGF-β1), a cytokine implicated in inflammatory processes that contribute to DDDRepair of Peripheral Nerve Injury Using Hydrogels Based on Self ....
SB-01 is a precisely engineered molecule composed of seven amino acids. Its development is spearheaded by Spine BioPharma, where it is also referred to by the investigational name Vicatertide or Remedisc. The peptide's core function is to antagonize TGF-β activitySpine BioPharma Completes Enrollment in Phase 3 Trial of .... TGF-β is a crucial cytokine found throughout the body, playing various roles in cell growth, differentiation, and immune response. However, its dysregulation can lead to excessive inflammation and tissue remodeling, which are hallmarks of degenerative conditions like DDD. SB-01 is designed to counteract these detrimental effects by binding to and inhibiting TGF-β signaling pathwaysSB-01 is a 7-amino acid peptidethat binds to and antagonizes TGFβ1 activity. TGFβ1 is an inflammatory cytokine which is often highly expressed in the ....
Transforming Growth Factor Beta 1 (TGF-β1) is a pleiotropic cytokine that, when overexpressed or dysregulated, can promote fibrosis and inflammation. In the context of degenerative disc disease, elevated levels of TGF-β1 are believed to contribute to the breakdown of the disc matrix and the onset of chronic painSpine BioPharma, Inc. Announces Completion of .... SB-01 functions by binding to TGF-β1, thereby blocking its interaction with cellular receptors and preventing the downstream signaling cascades that drive inflammation and tissue degradation. This targeted approach aims to halt or reverse the degenerative process at its source.
The most significant application of the SB-01 peptide has been in clinical trials for degenerative disc disease (DDD), specifically for chronic low back pain and associated functional disability.Spine BioPharma Announces Topline Results from Phase ... Spine BioPharma has conducted extensive research, including Phase 3 clinical studies, to confirm the safety and effectiveness of SB-01 For Injection. This formulation is designed for direct administration into the spinal disc, allowing for localized therapeutic actionSham response variability mars Spine's phase III pain trial.
The peptide is being evaluated as a potential first-in-class intradiscal pharmacologic treatment for DDD. Clinical trial results have explored various endpoints, including pain intensity, pain-related function, and overall disability. While some trial phases have reported mixed results regarding primary endpoints, secondary analyses have often shown promising trends in pain reduction and improved function, suggesting a potential benefit for a subset of patientsSpine BioPharma Completes Enrollment in Phase 3 Trial of .... The administration route as an injection into the spinal disc distinguishes SB-01 from systemic treatments, aiming for a more direct impact on the affected tissue while minimizing systemic side effects2022年5月11日—SB-01 is a 7-amino acid peptidethat binds to and antagonizes TGFβ1 activity. TGFβ1 is an inflammatory cytokine which is often highly ....
Beyond its primary investigation for DDD, the mechanism of SB-01's action suggests potential applications in other conditions where TGF-β dysregulation plays a role. Research into orthopaedic sports medicine and the repair of injuries, such as peripheral nerve injuries, sometimes involves peptides that modulate similar pathways. While SB-01's development is heavily concentrated on its use in DDD, the broader understanding of TGF-β inhibition opens avenues for future explorationSB-01 is a synthetic 7-amino acid peptidethat binds to and induces down regulation of Transforming Growth Factor Beta 1 (TGFβ1)..
The journey of SB-01 peptide, or Vicatertide, highlights the ongoing effort to develop targeted therapies for chronic pain conditions.Spine BioPharma, Inc. Announces Agreement with Ensol ... Its specific design as a 7-amino acid synthetic peptide targeting TGF-β1 positions it as an innovative approach to managing the complex pathology of degenerative disc disease. Continued analysis of clinical data and potential future research will further define its role in therapeutic interventions.
Join the newsletter to receive news, updates, new products and freebies in your inbox.